UY36098A - Compuesto 1,1?-adipoilbis(pirrolidina-2-carboxilato) de (2r,2?r)-bis(((((tetrahidro-2h-piran-4- il)oxi)carbonil)oxi)metilo), para el tratamiento de la amiloidosis sistémica. - Google Patents

Compuesto 1,1?-adipoilbis(pirrolidina-2-carboxilato) de (2r,2?r)-bis(((((tetrahidro-2h-piran-4- il)oxi)carbonil)oxi)metilo), para el tratamiento de la amiloidosis sistémica.

Info

Publication number
UY36098A
UY36098A UY0001036098A UY36098A UY36098A UY 36098 A UY36098 A UY 36098A UY 0001036098 A UY0001036098 A UY 0001036098A UY 36098 A UY36098 A UY 36098A UY 36098 A UY36098 A UY 36098A
Authority
UY
Uruguay
Prior art keywords
oxi
adipoylbis
piran
carboxylate
bis
Prior art date
Application number
UY0001036098A
Other languages
English (en)
Spanish (es)
Inventor
Denis Alexis
Mirguet Olivier
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of UY36098A publication Critical patent/UY36098A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
UY0001036098A 2014-04-29 2015-04-27 Compuesto 1,1?-adipoilbis(pirrolidina-2-carboxilato) de (2r,2?r)-bis(((((tetrahidro-2h-piran-4- il)oxi)carbonil)oxi)metilo), para el tratamiento de la amiloidosis sistémica. UY36098A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1407506.3A GB201407506D0 (en) 2014-04-29 2014-04-29 Novel compound

Publications (1)

Publication Number Publication Date
UY36098A true UY36098A (es) 2015-11-30

Family

ID=50972033

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036098A UY36098A (es) 2014-04-29 2015-04-27 Compuesto 1,1?-adipoilbis(pirrolidina-2-carboxilato) de (2r,2?r)-bis(((((tetrahidro-2h-piran-4- il)oxi)carbonil)oxi)metilo), para el tratamiento de la amiloidosis sistémica.

Country Status (26)

Country Link
US (3) US9701668B2 (OSRAM)
EP (1) EP3137457B1 (OSRAM)
JP (1) JP6445046B2 (OSRAM)
KR (1) KR20160145617A (OSRAM)
CN (1) CN106459016B (OSRAM)
AR (1) AR100204A1 (OSRAM)
AU (1) AU2015252184B2 (OSRAM)
BR (1) BR112016025129A2 (OSRAM)
CA (1) CA2947060C (OSRAM)
CL (1) CL2016002721A1 (OSRAM)
CR (1) CR20160508A (OSRAM)
DO (1) DOP2016000292A (OSRAM)
EA (1) EA032129B1 (OSRAM)
ES (1) ES2731253T3 (OSRAM)
GB (1) GB201407506D0 (OSRAM)
IL (2) IL248249A0 (OSRAM)
MA (1) MA39406B1 (OSRAM)
MX (1) MX2016014246A (OSRAM)
MY (1) MY191088A (OSRAM)
PE (1) PE20161558A1 (OSRAM)
PH (1) PH12016502006B1 (OSRAM)
SG (1) SG11201608371RA (OSRAM)
TW (1) TWI676624B (OSRAM)
UA (1) UA119871C2 (OSRAM)
UY (1) UY36098A (OSRAM)
WO (1) WO2015165833A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737505B2 (en) 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
GB201518950D0 (en) 2015-10-27 2015-12-09 Glaxosmithkline Ip Dev Ltd Compound
GB202213162D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Prodrugs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT915088E (pt) 1997-10-31 2003-01-31 Hoffmann La Roche Derivados de d-prolina
US6903129B2 (en) * 2001-12-14 2005-06-07 Hoffman-La Roche Inc. D-proline prodrugs
EP1636240A1 (en) 2003-06-05 2006-03-22 Pfizer Products Inc. Beta-lactamase inhibitor prodrug
GB0313386D0 (en) 2003-06-10 2003-07-16 Univ London Treatment of disease
EP1870412A4 (en) 2005-04-12 2009-12-30 Meiji Seika Kaisha 2-THIOETHENYLCARBAPENEM DERIVATIVE
GB0712503D0 (en) 2007-06-27 2007-08-08 Therapeutics Pentraxin Ltd Use
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
US9737505B2 (en) 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline

Also Published As

Publication number Publication date
TW201625598A (zh) 2016-07-16
EP3137457A1 (en) 2017-03-08
BR112016025129A2 (pt) 2017-08-15
PH12016502006A1 (en) 2016-12-19
IL279120A (en) 2021-01-31
IL248249A0 (en) 2016-11-30
JP6445046B2 (ja) 2018-12-26
AR100204A1 (es) 2016-09-21
US20180099955A1 (en) 2018-04-12
CA2947060C (en) 2023-09-26
SG11201608371RA (en) 2016-11-29
WO2015165833A1 (en) 2015-11-05
UA119871C2 (uk) 2019-08-27
US20170267665A1 (en) 2017-09-21
JP2017514829A (ja) 2017-06-08
ES2731253T3 (es) 2019-11-14
DOP2016000292A (es) 2017-11-15
PE20161558A1 (es) 2017-01-06
AU2015252184B2 (en) 2017-11-02
US9873686B2 (en) 2018-01-23
EP3137457B1 (en) 2019-04-17
US20160075694A1 (en) 2016-03-17
US10597385B2 (en) 2020-03-24
TWI676624B (zh) 2019-11-11
MX2016014246A (es) 2017-02-06
AU2015252184A1 (en) 2016-10-27
EA032129B1 (ru) 2019-04-30
EA201692185A1 (ru) 2017-06-30
CR20160508A (es) 2017-03-10
US9701668B2 (en) 2017-07-11
GB201407506D0 (en) 2014-06-11
MY191088A (en) 2022-05-30
KR20160145617A (ko) 2016-12-20
MA39406B1 (fr) 2018-04-30
CN106459016B (zh) 2019-11-01
CN106459016A (zh) 2017-02-22
PH12016502006B1 (en) 2016-12-19
MA39406A1 (fr) 2017-07-31
CL2016002721A1 (es) 2017-01-20
CA2947060A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
AR132544A2 (es) ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
ECSP13012609A (es) Composición farmacéutica
CR20110509A (es) Composicion farmaceutica
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
UY35427A (es) Compuestos y sus usos en la modulación de la hemoglobina
UY35425A (es) Compuestos y sus usos en la modulación de la hemoglobina
UY35426A (es) Compuestos y sus usos en la modulación de la hemoglobina
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
CL2014001060A1 (es) Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades.
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
CO6382089A2 (es) Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias
CR20170376A (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 con lixisenatida
CL2016000026A1 (es) Nuevos derivados de azabencimidazol
CO2019004131A2 (es) Glicinato de metformina, composiciones farmacéuticas que comprenden la misma, y métodos de uso de la misma
UY33258A (es) Proteinas de union a antigeno
CL2017002326A1 (es) Tratamiento de pacientes con diabetes mellitus tipo 2
UY36098A (es) Compuesto 1,1?-adipoilbis(pirrolidina-2-carboxilato) de (2r,2?r)-bis(((((tetrahidro-2h-piran-4- il)oxi)carbonil)oxi)metilo), para el tratamiento de la amiloidosis sistémica.
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
CL2016001054A1 (es) Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma
ES2478793B2 (es) Composición de nanofilamentos para el tratamiento de tumores
ITUB20169928A1 (it) Formulazioni farmaceutiche per il trattamento del diabete
ES2540457B2 (es) Procedimiento de obtención de extractos de hojas de Corema album y su aplicación terapéutica

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20230505